S209: PRIMARY RESULTS FROM THE PHASE 3 SHINE STUDY OF IBRUTINIB IN COMBINATION WITH BENDAMUSTINE-RITUXIMAB (BR) AND R MAINTENANCE AS A FIRST-LINE TREATMENT FOR OLDER PATIENTS WITH MANTLE-CELL LYMPHOMA. (23rd June 2022) - Wang, M. L.; Jurczak, W.; Jerkeman, M.; Trotman, J.; Zinani, P. L.; Belada, D.; Boccomini, C.; Flinn, I. W.; Giri, P.; Goy, A.; Hamlin, P. A.; Hermine, O.; et al.